Prognostic value of sequential 18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nicholas Peter Verdini, Ilhan Lim, Esther Mena, Liza Lindenberg, Amir Mortazavi, Sumanta K. Pal, Primo Lara, Katherine Graap, Marissa Mallek, Corrine Keen, Ryan Thompson, Christian Mayfield, Corinne Turrell, Jacqueline Cadena, Biren Saraiya, Ray L Lilly, Michael V. Knopp, Chadwick Wright, Seth M. Steinberg, Andrea B. Apolo
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, City Of Hope National Medical Center, UC Davis Comprehensive Cancer Center, Rutgers Cancer Institute, The Ohio State University
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947775727